David B. Agus, MD

Professor of Medicine and Biomedical Engineering

Director, Lawrence J. Ellison Institute for Transformative Medicine of USC

Director, USC Center for Applied Molecular Medicine

Image of David B. Agus, MD
Is this your profile? Click to edit

Overview

David B. Agus is a professor of medicine and engineering at the University of Southern California’s Keck School of Medicine and Viterbi School of Engineering. He is the founding director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. A medical oncologist, Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs. An international leader in new technologies and approaches for personalized healthcare, Dr. Agus serves in leadership roles at the World Economic Forum and the Global Health Security Consortium. He is also a CBS News contributor. Dr. Agus’ three books “The End of Illness”, “A Short Guide to a Long Life” and “The Lucky Years: How to Thrive in the Brave New World of Health” are all New York Times and international bestsellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University, and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital and fellowship at Memorial Sloan-Kettering Cancer Center.

Awards

  • American Cancer Society: Physician Research Award, 1996
     – 2001
  • Sloan-Kettering Institute: Clinical Scholar Award, 1996
  • American Cancer Society: Clinical Oncology Fellowship Award, 1994
  • HealthNetwork Foundation: Excellence Award, 2008
  • Geoffrey Beene Foundation: Rock Stars of Science™, 2009
  • Biotech Humanitarian Award: Selected Judge, 2009
  • USC Association of Trojan Leagues: Outstanding Service Award, 2013
  • American College of Physicians: Fellow, 2016
  • Ellis Island Medal of Honor: Medalist, 2017

Research Funding

  • (PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
    NIH · R01CA180149 · Sep 5, 2013 – Jul 31, 2018 · Role: Principal Investigator
  • UCLA SPORE in Prostate Cancer
    NIH · P50CA092131 · Jul 1, 2001 – Aug 31, 2024 · Role: Co-Principal Investigator

Publications

  • Deep learned tissue “fingerprints” classify breast cancers by ER/PR/Her2 status from H&E images. Sci Rep. 2020 04 29; 10(1):7275.. View in PubMed
  • Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2021 03; 24(1):61-68.. View in PubMed
  • Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA). BMC Res Notes. 2019 May 15; 12(1):275.. View in PubMed
  • Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City. Addict Behav. 2019 06; 93:14-19.. View in PubMed
  • Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens. NPJ Breast Cancer. 2018; 4:32.. View in PubMed
  • Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol. 2017 11; 18(11):e653-e706.. View in PubMed
  • Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clin Genitourin Cancer. 2017 Jul 14.. View in PubMed
  • JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Mol Cancer Ther. 2017 08; 16(8):1645-1657.. View in PubMed
  • Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial. Am Heart J. 2017 Jul; 189:94-102.. View in PubMed
  • The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older. PLoS One. 2016; 11(11):e0166103.. View in PubMed